Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Google Changes EU Spam Policy Amid Antitrust Scrutiny 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
 and Lead Plaintiff Deadline: May 28, 2018 - EconoTimes)
Add as a preferred source on Google
NEW YORK, April 03, 2018 -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Solid Biosciences Inc. ("Solid" or the "Company") (NASADAQ:SLDB) and certain of its officers, on behalf of shareholders who purchased Solid securities (1) in Solid’s initial public offering on or about January 25, 2018; or (2) on the open market from January 25, 2018 through March 14, 2018, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/sldb.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) Solid’s lead drug candidate, SGT-001, had a high likelihood of causing adverse events in patients; (2) The company misled investors regarding the toxicity of SGT-001; and (3) consequently, defendants’ statements in the Registration Statement regarding Solid Biosciences’ business, operations, and prospects were materially false and/or misleading.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/sldb or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Solid you have until May 28, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
